IP Verse

Corticosteroid Compositions - EP2214679

The patent EP2214679 was granted to Meritage Pharma on Mar 27, 2019. The application was originally filed on Nov 12, 2008 under application number EP08850126A. The patent is currently recorded with a legal status of "Revoked".

EP2214679

MERITAGE PHARMA
Application Number
EP08850126A
Filing Date
Nov 12, 2008
Status
Revoked
Sep 24, 2021
Publication Date
Mar 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AECHTERDec 27, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
DR FALK PHARMADec 19, 2019LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS6291445
DESCRIPTIONUS6686346
DESCRIPTIONUS6986904
DESCRIPTIONWO2008070129
INTERNATIONAL-SEARCH-REPORTUS2004023935
INTERNATIONAL-SEARCH-REPORTUS2006193783
INTERNATIONAL-SEARCH-REPORTUS2007111978
INTERNATIONAL-SEARCH-REPORTUS6899099
OPPOSITIONEP1310243
OPPOSITIONUS2007111978
OPPOSITIONUS6598603
OPPOSITIONWO2009064457
SEARCHUS2007111978
SEARCHUS6598603

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- BAUER, Pharmazeutische Technologie, (19970000), pages 154 - 157 ; 446-447, XP055671559
OPPOSITION- "Excipients for Oral Liquid Formulations", Katdare A. et al, Excipient Development for Pharmaceutical, Biotechnology and Drug Delivery Systems, USA, CRC Press, (20060000), pages 155 - 180, XP055667826
OPPOSITION- FDA Drug Safety Data Report - Pulmicort®, XP055671554
OPPOSITION- FIEDLER, Lexikon der Hilfsstoffe, (20020000), vol. 1, pages 663 - 665, XP055671564
OPPOSITION- FIEDLER, Lexikon der Hilfsstoffe, (20020000), vol. 2, page 1081, XP055671562
OPPOSITION- JUDITH BLAKE, "Splenda under fire over claims", The Seattle Times -Press release article, (20050302), XP055671556
OPPOSITION- Rote Liste 2000 - Pulmicort®, XP055671550
OPPOSITION- PONCHEL G., "Formulation of oral mucosal drug delivery systems for the systemic delivery of bioactive materials", Advanced Drug Delivery Reviews, (19940100), vol. 13, no. 1-2, pages 75 - 87, XP023744826
OPPOSITION- THORBURN et al., "Topical corticosteroids and lesions of the oral mucosa", Advanced Drug Delivery Reviews, (19940100), vol. 13, no. 1-2, pages 135 - 149, XP023861790
OPPOSITION- ACEVES ET AL, "Topical viscous budesonide suspension for treatment of eosinophilic esophagitis", Journal of Allergy Clin. Immunol., (20050900), vol. 116, no. 3, pages 705 - 706, XP005068207
OPPOSITION- VAGHI et al., "In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol", Pulm Pharmacol Ther., (20041220), vol. 18, no. 2, doi:10.1016/j.pupt.2004.10.004, pages 151 - 3, XP004706668
OPPOSITION- HANKO et al., "Determination of Sucralose in Splenda and a Sugar-Free Beverage Using High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection.", J. Agric. Food Chem., (20040000), vol. 52, pages 4375 - 4379, XP055671568
OPPOSITION- LIACOURAS et al., "Primary Eosinophilic Esophagitis in Children: Successful Treatment with Oral Corticosteroids", Journal of Pediatric Gastroenterology & Nutrition, (19980400), vol. 26, no. 4, pages 380 - 385, XP055667821
OPPOSITION- FURUTA G. T, "Eosinophils in the Esophagus: Acid is Not the Only Cause", Journal of Pediatric Gastroenterology & Nutrition, (19980400), vol. 26, no. 4, pages 468 - 471, XP055667822
SEARCH- S Freers, "Maltodextrin", Handbook of Pharmaceutical Excipients - Fifth Edition, UK / USA, Pharmaceutical Press, (20060101), pages 442 - 444, ISBN 978-0-85-369618-6, XP055075444 [A] 1-40 * Monography part 7 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents